The combined company will have an estimated post-transaction enterprise value of ~$302M assuming a proposed future $40.0M in PIPE & 100% redemptions by BlueRiver public shareholders. The transaction is expected to close in Q4’23 or early 2024
SST shareholders will roll 100% of their existing SST equity holdings & are expected to own equity-linked securities representing ~70% of the combined company on a non-fully diluted basis. The combined company will operate as Spinal Stabilization Technologies and be listed on an approved stock exchange
In Mar 2021, the US FDA granted the breakthrough device designation to SST’s PerQdisc Nucleus Replacement System, an innovative lumbar intervertebral disc nucleus replacement
Ref: Businesswire | Image: Spinal Stabilization Technologies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
